by Chris Dokomajilar | Nov 22, 2023 | Analysis, M&A
This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk’s acquisition of Inversago Pharma offering shareholders up to...
by Chris Dokomajilar | Nov 6, 2023 | Analysis, Funding, M&A, Partnership Deals
We have been tracking advances within biopharma and medtech deals and financing through Q3 2023 to see what might be shaping up for 2024. R&D deals took center stage, with Pfizer’s collaboration with Flagship Pioneering, promising an exclusive global option...
by Chris Dokomajilar | Aug 4, 2023 | Analysis, M&A
Biopharma M&A activity in Q2 2023 picked up as the number of therapeutics and discovery platform company acquisitions tracked higher. The second quarter of 2023 saw 27 M&A deals for a total upfront of $27.4 billion or $28.1 billion when counting contingent...
by Chris Dokomajilar | Aug 1, 2023 | Analysis, Funding, M&A, Partnership Deals
The biopharmaceutical industry outlook for the new quarter remains dynamic and promising, characterized by significant deals in the first half. Galderma’s private placement of $1 billion aims to strengthen its dermatology position and leverage its integrated...
by Chris Dokomajilar | Jul 15, 2023 | Analysis, M&A
We are looking at mergers and acquisitions in the neurology space through June 2023. As with the broader biopharma sector, neurology deal flow has been down since 2020. The year started with a decent number of billion-plus acquisitions in other biopharma therapeutic...
by Chris Dokomajilar | Jun 20, 2023 | Analysis, M&A
The M&A landscape in the dermatology sector illustrates an enticing market that attracts ongoing investment. Analyzing the data from the past three years reveals a consistent level of activity, suggesting mergers and acquisitions in dermatology are seeing...
